Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
about
A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.Combinatorial drug delivery approaches for immunomodulation.Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes.Cancer nanomedicine: progress, challenges and opportunities.In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Unraveling the complex story of immune responses to AAV vectors trial after trial.A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.The Future of Immunotherapy: A 20-Year Perspective.Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.Improving Vaccine and Immunotherapy Design Using Biomaterials.Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.Facile assembly and loading of theranostic polymersomes via multi-impingement flash nanoprecipitation.Modulating the immune system through nanotechnology.Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
P2860
Q38650286-8EEE0EF2-0238-4B62-AF85-590E2A567C6EQ38680602-78F63C39-913D-4B63-93EE-9A1C08A32E19Q38754057-71DC58CF-B423-4F67-BB49-CF1D46F7CF22Q39005226-C5E107DC-BBCF-4E14-8186-E81B0D841F4EQ39245827-98059402-2954-46A5-8466-B6E8BC383228Q40073271-D3F2955F-2236-4C32-869C-B606928DFEFFQ40140649-2BF3BF05-0A3B-4909-9F55-BDCEC4355809Q47162933-CBB34A93-2B41-4D06-888B-AA6357D58E3AQ47222860-BC8A898F-8A3B-4E6C-8ADD-406C63F1D91DQ47234002-D2CB840A-0C8C-4CDE-9D21-8BD23299B5AFQ47676665-A3A47E79-F8F6-4177-B4C9-326CCB2A33C5Q47771876-11061F1F-C254-48EF-85B1-9822D59F13D6Q47890422-A5A7AA2D-DE73-4E54-BE43-D0373A3AAC42Q48630939-616BB109-9460-4941-9037-196380D88852Q50322302-042D80B3-4D3F-46F5-8F41-7CDF3D640DCEQ50420436-05774826-C5EC-4E90-8B7C-FFFB6F39A6E0Q50885724-6C5B42F4-2CBD-4E91-8C9D-6C2951B28506Q52723975-FD72E338-5705-4AD9-A179-931E15804FC5Q55049471-604DA6B7-7063-4E38-8E2C-4B39CCC8D9C7
P2860
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@en
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@nl
type
label
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@en
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@nl
prefLabel
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@en
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@nl
P2093
P2860
P356
P1476
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
@en
P2093
Aaron P Griset
Aditi Chalishazar
Conlin O'Neil
David H Altreuter
Erica Browning
Joseph D Ferrari
Lloyd Johnston
Nelly Viseux
Pallavi N Kolte
P2860
P2888
P304
P356
10.1038/NNANO.2016.135
P407
P577
2016-08-01T00:00:00Z